FY2025 EPS Estimates for BioMarin Pharmaceutical Inc. Cut by Leerink Partnrs (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at Leerink Partnrs reduced their FY2025 EPS estimates for BioMarin Pharmaceutical in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of $1.98 per share for the year, down from their prior estimate of $2.16. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s FY2026 earnings at $2.37 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The business had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. During the same quarter in the previous year, the firm posted $0.11 earnings per share. BioMarin Pharmaceutical’s revenue was up 20.2% compared to the same quarter last year.

Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Piper Sandler lowered their target price on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Canaccord Genuity Group reissued a “hold” rating and set a $91.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 29th. Robert W. Baird decreased their price objective on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a report on Tuesday, January 30th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $101.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, December 21st. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.61.

BioMarin Pharmaceutical Trading Down 0.4 %

Shares of BioMarin Pharmaceutical stock opened at $90.07 on Thursday. The firm has a market capitalization of $17.00 billion, a PE ratio of 102.35, a price-to-earnings-growth ratio of 1.68 and a beta of 0.31. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57. The company’s fifty day moving average price is $87.61 and its two-hundred day moving average price is $89.11. BioMarin Pharmaceutical has a 52-week low of $76.02 and a 52-week high of $99.56.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $88.28, for a total value of $1,324,200.00. Following the sale, the director now directly owns 419,602 shares in the company, valued at $37,042,464.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Jean Jacques Bienaime sold 15,000 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $88.28, for a total value of $1,324,200.00. Following the completion of the transaction, the director now directly owns 419,602 shares of the company’s stock, valued at $37,042,464.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Henry J. Fuchs sold 35,341 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the transaction, the insider now directly owns 212,117 shares of the company’s stock, valued at $18,068,126.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 103,229 shares of company stock worth $9,062,967. Company insiders own 1.84% of the company’s stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently modified their holdings of the business. KB Financial Partners LLC raised its stake in BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. ICA Group Wealth Management LLC acquired a new position in BioMarin Pharmaceutical during the fourth quarter worth about $31,000. Acadian Asset Management LLC increased its stake in shares of BioMarin Pharmaceutical by 395.4% in the first quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 344 shares during the period. Castleview Partners LLC acquired a new position in shares of BioMarin Pharmaceutical in the third quarter valued at approximately $35,000. Finally, MayTech Global Investments LLC acquired a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $36,000. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.